Role of Genomic Instability Scores in Treatment Selection

Video content above is prompted by the following:

1. Dr Chan to ask Dr Herzog: How do genomic instability scores influence treatment selection and sequencing in ovarian cancer, particularly for patients with HRD vs HRP profiles?

• In what ways do these scores guide the use of PARP inhibitors or other targeted therapies in the maintenance setting?
• Are there scenarios where genomic instability scores might lead you to modify your standard approach to treatment?

2. Dr Herzog to ask Dr Chan: Please comment on any challenges when treating the HRP patient population